Announcements Trials
Browse Landscape

Phase

Phase NA 64Phase 2 5Phase 1 5Phase 4 3Phase EARLY_PHASE1 2Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Thoracic 2Gastrointestinal 2Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Barrett Esophagus 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Radiation 24Panitumumab 24Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Blood Specimen Collection × Gastrointestinal × Clear all
NCT06332274 2025-05-13

UMBRELLA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
717 enrolled
GastrointestinalSarcomaThoracic

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01209013 2012-05-08

Oedisse

Pinnacle Biologics Inc.

Phase 3 Withdrawn
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡